Of the 49 patients who received study treatment, 20 (41%) had therapy-related acute myeloid leukaemia or had therapy-related secondary acute myeloid leukaemia, 24% of patients had more than one mutation of TP53 and 80% of patients had VAF > 50%. Here, TP53 is linked to acute myeloid leukemia.